Wuhan Vanz Pharm Inc.

 

Wuhan Vanz Pharm Inc., Your reliable supplier!

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Home ProductsActive Pharmaceutical Ingredient

CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8

Good quality Pharmaceutical Intermediates for sales
Good quality Pharmaceutical Intermediates for sales
I am very happy to cooperate with your company for nearly three years, thank you very attentive service, thank you for the excellent product quality.

—— Stephnie

You always have very fast delivery, very happy to cooperate with you. Thank you.

—— John

Very pleased to become your customer, and very happy for our cooperation, hope to be your long-term parter.

—— Sara

we received the package, very fast, the quality is very good, will continue to buy your products.

—— Luice

I have emailed you a couple times and they get returned as undeliverable. Yes. I am happy with the powders. thank you.

—— Bryan

I'm Online Chat Now

CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8

China CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8 supplier
CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8 supplier CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8 supplier

Large Image :  CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8

Product Details:

Place of Origin: China
Brand Name: Vanz
Certification: ISO9001
Model Number: 302962-49-8

Payment & Shipping Terms:

Minimum Order Quantity: 1g
Packaging Details: bags or drum
Delivery Time: 3-5 days
Payment Terms: T/T, Western Union, MoneyGram
Supply Ability: 2kg per month
Contact Now
Detailed Product Description
Name: Dasatinib CAS: 302962-49-8
Appearance: White Crystal Powder COA: Available
Assay: 99%min Stock: Available

CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8

 

Introduction

 

Dasatinib, previously known as BMS-354825, is a cancer drug produced by Bristol-Myers Squibb and sold under the trade name Sprycel. Dasatinib is an oral Bcr-Abl tyrosine kinase inhibitor (inhibits the "Philadelphia chromosome") and Src family tyrosine kinase inhibitor approved for first line use in patients with chronic myelogenous leukemia (CML)[1] and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It is being evaluated for use in numerous other cancers, including advanced prostate cancer.

 

Efficacy

 

In a Phase I dose escalation study published in June 2006, dasatinib was tested in patients who were resistant to or who could not tolerate imatinib.[2] Complete hematological responses[3] were seen in 37 of 40 patients with chronic-phase CML. Major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML in blast crisis, or Ph+ ALL.

 

Medical Uses

 

Oxaliplatin is used for treatment of colorectal cancer, typically along with folinic acid and 5-fluorouracil in a combination known as FOLFOX. Oxaliplatin has been compared with other platinum compounds used for advanced cancers, such as cisplatin and carboplatin.

 

Product Name Dasatinib monohydrate
Appearance White to off- white crystalline powder
Odor &Taste Characteristic
Test Method HPLC
Specification 98.5%min
Supplier vanz
CAS# 863127-77-9
Molecular Formula C22H26ClN7O2S.H2O
Molecular Weight 506.02
Structure Factory Supply Dasatinib Intermediate/CAS 863127-77-9/Dasatinib
Packing

N.W.25kgs

G.W.28kgs

Paper-drums and two plastic-bags inside.

Storage
Store in cool & dry place.Keep away from strong light and heat.
Shelf life
24 months when properly stored.

 

Side Effects

 

On October 11, 2011 the U.S. Food and Drug Administration (FDA) announced that dasatinib may increase the risk of a rare but serious condition in which there is abnormally high blood pressure in the arteries of the lungs (pulmonary hypertension, PAH). Symptoms of PAH may include shortness of breath, fatigue, and swelling of the body (such as the ankles and legs). In reported cases, patients developed PAH after starting dasatinib, including after more than one year of treatment.

Information about this risk has been added to the Warnings and Precautions section of the Sprycel drug label.

 

Cost

 

The Union for Affordable Cancer Treatment objected to the price of dasatinib, in a letter to the U.S. trade representative. The average wholesale price in the U.S. is $367 per day, twice the price in other high income countries.

 

The price in India, where the average annual per capita income is $1,570, and where most patients pay out of pocket, is Rs6627 ($108) a day. Indian manufacturers offered to supply generic versions for $4 a day, but, under pressure from the U.S., the Indian Department of Industrial Policy and Promotion refused to issue a compulsory license

 

 

CML Treatment Dasatinib Powder Active Pharmaceutical Ingredient CAS 302962-49-8

Contact Details
Wuhan Vanz Pharm Inc.

Contact Person: Amy

Tel: +8613277095342

Send your inquiry directly to us (0 / 3000)